NYSE - Nasdaq Real Time Price USD

Teva Pharmaceutical Industries Limited (TEVA)

Compare
20.94
-0.55
(-2.56%)
At close: January 10 at 4:00:02 PM EST
21.17
+0.23
+(1.10%)
After hours: January 10 at 7:59:46 PM EST
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
16,772,000.00
15,845,000.00
14,925,000.00
15,879,000.00
16,658,000.00
Cost of Revenue
8,413,000.00
8,200,000.00
7,952,000.00
8,284,000.00
8,933,000.00
Gross Profit
8,358,000.00
7,645,000.00
6,973,000.00
7,594,000.00
7,726,000.00
Operating Expense
4,630,000.00
4,451,000.00
4,283,000.00
4,495,000.00
4,668,000.00
Operating Income
3,728,000.00
3,194,000.00
2,690,000.00
3,099,000.00
3,058,000.00
Net Non Operating Interest Income Expense
-1,050,000.00
-1,095,000.00
-991,000.00
-962,000.00
-963,000.00
Other Income Expense
-3,208,000.00
-2,723,000.00
-4,859,000.00
-1,480,000.00
-6,500,000.00
Pretax Income
-530,000.00
-624,000.00
-3,163,000.00
658,000.00
-4,406,000.00
Tax Provision
689,000.00
-7,000.00
-643,000.00
211,000.00
-168,000.00
Earnings from Equity Interest Net of Tax
2,000.00
2,000.00
21,000.00
9,000.00
138,000.00
Net Income Common Stockholders
-959,000.00
-559,000.00
-2,446,000.00
417,000.00
-3,990,000.00
Diluted NI Available to Com Stockholders
-959,000.00
-559,000.00
-2,446,000.00
417,000.00
-3,990,000.00
Basic EPS
-0.85
-0.50
-2.12
0.38
-3.64
Diluted EPS
-0.85
-0.50
-2.12
0.38
-3.64
Basic Average Shares
1,127,250.00
1,119,000.00
1,110,000.00
1,102,000.00
1,095,000.00
Diluted Average Shares
1,127,250.00
1,119,000.00
1,110,000.00
1,107,000.00
1,095,000.00
Total Operating Income as Reported
482,000.00
433,000.00
-2,197,000.00
1,716,000.00
-3,572,000.00
Total Expenses
13,043,000.00
12,651,000.00
12,235,000.00
12,779,000.00
13,601,000.00
Net Income from Continuing & Discontinued Operation
-959,000.00
-559,000.00
-2,446,000.00
417,000.00
-3,990,000.00
Normalized Income
1,512,700.00
2,122,910.00
1,420,400.00
1,409,503.04
1,427,664.00
Interest Expense
984,000.00
1,029,000.00
930,000.00
891,000.00
901,000.00
Net Interest Income
-1,050,000.00
-1,095,000.00
-991,000.00
-962,000.00
-963,000.00
EBIT
454,000.00
405,000.00
-2,233,000.00
1,549,000.00
-3,505,000.00
EBITDA
1,510,000.00
1,558,000.00
-925,000.00
2,879,000.00
-1,948,000.00
Reconciled Cost of Revenue
8,413,000.00
8,200,000.00
7,952,000.00
8,284,000.00
8,933,000.00
Reconciled Depreciation
1,056,000.00
1,153,000.00
1,308,000.00
1,330,000.00
1,557,000.00
Net Income from Continuing Operation Net Minority Interest
-959,000.00
-559,000.00
-2,446,000.00
417,000.00
-3,990,000.00
Total Unusual Items Excluding Goodwill
-3,210,000.00
-2,709,000.00
-4,833,000.00
-1,461,000.00
-6,496,000.00
Total Unusual Items
-3,210,000.00
-2,709,000.00
-4,833,000.00
-1,461,000.00
-6,496,000.00
Normalized EBITDA
4,720,000.00
4,267,000.00
3,908,000.00
4,340,000.00
4,548,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-738,300.00
-27,090.00
-966,600.00
-468,496.96
-1,078,336.00
12/31/2020 - 2/16/1982

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

VTRS Viatris Inc.
11.67
-2.42%
 
KMDA Kamada Ltd.
7.41
+1.23%
 
TLRY Tilray Brands, Inc.
1.2300
-10.22%
 
BHC Bausch Health Companies Inc.
7.88
+0.64%
 
CGC Canopy Growth Corporation
2.4500
-7.89%
 
PRGO Perrigo Company plc
24.38
-2.67%
 
ACB Aurora Cannabis Inc.
4.1300
-6.56%
 
ITCI Intra-Cellular Therapies, Inc.
94.87
+14.91%
 
TAK Takeda Pharmaceutical Company Limited
12.95
-2.19%
 
ZTS Zoetis Inc.
163.32
-1.03%